Clinical Trial

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

Name: A Clinical Study on TIL for the Treatment of Advanced Solid Tumors — clinical trial record (NCT05087745)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT Number	NCT05087745
Lead Sponsor	Shanghai Juncell Therapeutics Collaborators: Sir Run Run Shaw Hospital
Conditions	Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects, Effects of Immunotherapy
Enrollment	50 participants
Start Date	2021-12-10
Primary Completion	2027-12-10 (estimated)
Study Completion	2029-12-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-05